Davos 2015: Wim Leereveld on health systems design

Access to Medicine Index

On January 22, during the World Economic Forum Annual Meeting, Index CEO and founder Wim Leereveld will be in Davos to discuss health systems leap-frogging in emerging economies. In a private session organised by the World Economic Forum, supported by the Boston Consulting Group

Wim will lead a group discussion about the strategic design of health systems, including how to select, incubate and scale up those initiatives that hold the most promise. In the same session, Edith Schippers, Dutch Minister of Health, Welfare and Sports, will lead a discussion about the role of governments in ensuring health systems are delivered successfully and sustainably.

Wim Leereveld: In the 2014 Access to Medicine Index, we identified many examples of how global pharmaceutical companies are helping low-income countries to leapfrog common challenges involved in building effective health systems as well as areas where solutions are still broadly lacking. Im looking forward to sharing these insights in Davos later this week.

The session is part of a three-year project that aims to reach a holistic understanding of the challenges facing emerging economies and to create strategies for building accessible, high-quality and cost-effective health systems. The project will identify pathways that enable emerging economies to leap over problems encountered by developed economies in building such systems.

Sign up to receive updates about our work.

About the Access to Medicine Index

The Access to Medicine Index analyses the top 20 research-based pharmaceutical companies with products for high-burden diseases in low- and middle-income countries. The Index ranks these companies according to their efforts to improve access to medicine in seven areas of corporate behaviour, including pricing, patents, ethical behaviour and donations. It covers 107 low- and middle-income countries and 50 high-burden diseases, and examines eight types of products, from medicines to vaccines to diagnostics. The Index identifies best practices, highlights where progress is being made, and uncovers where critical action is still required. In this way, the Index provides both an incentive and a guide for pharmaceutical companies to do more to improve access to medicine. It is published every two years by the Access to Medicine Foundation, an independent non-profit organisation.

About the Access to Medicine Foundation

The Access to Medicine Foundation is a non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income countries by stimulating and guiding the pharmaceutical industry to play a greater role in improving access to medicine. The Foundation is funded by the Bill & Melinda Gates Foundation, the Dutch Ministry of Foreign Affairs and the UK Department for International Development. For ten years, the Foundation has been building consensus on the role for the pharmaceutical industry in improving access to medicine and vaccines. It published its first benchmark of industry activity in this area in 2008, in the first Access to Medicine Index. The fifth Access to Medicine Index will be published in 2016.